Shares of Veru are on the rise after Oppenheimer analyst Leland Gershell started coverage of the stock with an Outperform rating and a $5 price target. With a profile "rarely seen" within small-cap biopharma, Veru generates commercial revenue that meaningfully offsets R&D burn, has a near-term product opportunity that is both risk-mitigated and high-margin, and offers significant upside prospects from new chemical entities for unmet needs in prostate cancer, he contends. The analyst believes mid-2019 data readouts on zuclomiphene, in Phase 2 for the management of hot flashes in prostate cancer patients receiving androgen-deprivation therapy, and on VERU-111, a firstin-class oral anti-tubulin in Phase 1b/2 for Zytiga/Xtandi-resistant metastatic prostate cancer, will catalyze investor attention to this off-the-radar name.